🇺🇸 FDA

Intelligence · Clinical Pipeline

Neurology & CNS R&D Pipeline

Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Programs
676

Quick answer

Neurology & CNS: NovaPharmaNews indexes 676 neurology & cns clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Top sponsors

Page 11 of 15

  1. CERE-110: Adeno-Associated Virus Delivery of NGF

    SANGAMO THERAPEUTICS, INC

    Alzheimer's Disease

    phase 1 gene therapy completed

    1 trial

  2. CERE-120: AAV2-NTN

    SANGAMO THERAPEUTICS, INC

    Parkinson's Disease

    phase 1 gene therapy completed

    1 trial

  3. CNCT19 cell injection

    Juventas Cell Therapy

    Neurological Autoimmune Diseases

    phase 1 mab active

    1 trial

  4. Carbidopa

    United Therapeutics Europe Ltd

    Multiple Sclerosis

    phase 1 small molecule completed

    1 trial

  5. Characterization of Immune Response in Participants from a Posdinemab Study

    Janssen-Cilag International N.V.

    Early Alzheimer's disease

    phase 1 other active

    1 trial

  6. Citalopram

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Depression

    phase 1 small molecule active

    1 trial

  7. DIPHENHYDRAMINE, METHYLPREDNISOLONE, PARACETAMOL, ublituximab, Ublituximab, ublituximab, CETIRIZINE, DEXAMETHASONE

    TG THERAPEUTICS, INC.

    Relapsing multiple sclerosis, Myasthenia Gravis

    phase 1 small molecule active

    1 trial

  8. DNL201

    Denali Therapeutics

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

  9. DNL628

    Denali Therapeutics

    Alzheimer Disease, Early Onset

    phase 1 small molecule active

    1 trial

  10. DNL747

    Denali Therapeutics

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  11. Divalproex Sodium Extended-release 250mg

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 1 small molecule active

    1 trial

  12. Donepezil Dihydroxynaphthalate for Injection

    Shanghai University of Traditional Chinese Medicine

    Alzheimer Disease

    phase 1 small molecule active

    1 trial

  13. Dose dense re-challenge of high dose methotrexate (hd-mtx) with glucarpidase (cpg2) for relapsed primary cns lymphoma (pcnsl): A phase 1 trial (METHOGLU)

    Pari Pharma GmbH

    Oncology: RELAPSED PRIMARY CNS LYMPHOMA

    phase 1 other active

    1 trial

  14. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 1 small molecule completed

    1 trial

  15. ENA-001

    BRIGHT MINDS BIOSCIENCES INC.

    Respiratory Depression

    phase 1 small molecule active

    1 trial

  16. Effect of NBI-921355 on corticospinal excitability in healthy participants

    NEUROCRINE BIOSCIENCES INC

    Epilepsy

    phase 1 other active

    1 trial

  17. First-in-Human Study of ALN-SNCA in Adult Participants with Early Parkinson’s Disease (PD)

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 1 other active

    1 trial

  18. First-in-Human Study of RO7812653

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitive Impairment due to AD, or probable AD dementia)

    phase 1 other active

    1 trial

  19. GRoningen Early-PD Ambroxol Treatment Pharmacokinetics

    Disc Medicine

    Parkinson's disease

    phase 1 other active

    1 trial

  20. GT-02287

    Gain Therapeutics

    Parkinson Disease

    phase 1 small molecule active

    1 trial

  21. Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]

    S.L

    STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder

    phase 1 small molecule active

    1 trial

  22. HEC122505MsOH

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

  23. Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer’s Disease (AD)

    IONIS PHARMACEUTICALS INC

    Alzheimer’s Disease in Individuals with Down Syndrome

    phase 1 other active

    1 trial

  24. Human Amniotic Epithelial Stem Cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Parkinson's Disease

    phase 1 mab completed

    1 trial

  25. ION269

    IONIS PHARMACEUTICALS INC

    Alzheimer Disease

    phase 1 small molecule terminated

    1 trial

  26. IONIS MAPTRx

    IONIS PHARMACEUTICALS INC

    Mild Alzheimer's Disease

    phase 1 small molecule completed

    1 trial

  27. IRX4204

    IO Biotech

    Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  28. ITI-214 Dose A

    Takeda

    Schizophrenia

    phase 1 small molecule terminated

    1 trial

  29. Infudopa i.v.

    Lxo Ireland Designated Activity Company

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

  30. Ixazomib (NINLARO®) capsules / Matching placebo capsules

    Takeda

    Relapsing Remitting Multiple Sclerosis

    phase 1 small molecule active

    1 trial

  31. Jiedu Tongluo granules

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Post-stroke Depression

    phase 1 small molecule completed

    1 trial

  32. KHK6640

    KYOWA KIRIN AUSTRALIA PTY LTD

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  33. KYV-101 (Biological) - 0.33 ×10^8 cells

    Kyverna Therapeutics

    Progressive Multiple Sclerosis

    phase 1 mab active

    1 trial

  34. KYV-101 anti-CD19 CAR-T cell therapy

    Kyverna Therapeutics

    Multiple Sclerosis

    phase 1 mab active

    1 trial

  35. Ketamine

    United Therapeutics Europe Ltd

    Acute Depression

    phase 1 small molecule terminated

    1 trial

  36. LBT-3627

    Biotech Pharmaceutical Co.,

    Parkinson Disease

    phase 1 small molecule active

    1 trial

  37. LCAR-AIO T cells

    Nanjing Legend Biotech Co.

    Multiple Sclerosis (MS)

    phase 1 mab active

    1 trial

  38. LX1001

    Lexeo Therapeutics

    Alzheimer Disease

    phase 1 mab active

    1 trial

  39. LY4006896

    Eli Lilly and Company

    Parkinson Disease

    phase 1 small molecule active

    1 trial

  40. Levodopa

    Blackmores Limited

    Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  41. Levodopa Cyclops®

    BRIGHT MINDS BIOSCIENCES INC.

    Parkinson

    phase 1 other completed

    1 trial

  42. Lu AF28996

    H. Lundbeck A/S

    Parkinson Disease

    phase 1 small molecule active

    1 trial

  43. Lu AF28996 in Patients With Parkinson's Disease

    H. Lundbeck A/S

    Parkinson's Disease

    phase 1 other active

    1 trial

  44. MEDI1341

    Takeda

    Parkinson's Disease

    phase 1 small molecule completed

    2 trials

  45. MRx0029

    4D Molecular Therapeutics

    Idiopathic Parkinson Disease

    phase 1 mab terminated

    1 trial

  46. Motivational Interviewing

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 1 other completed

    1 trial

  47. N-acetylcysteine

    Ultragenyx UK Limited

    Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  48. NDX-1017

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many neurology & cns pipeline programs are tracked?

676 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.